CYP24 inhibition preserves 1α,25-dihydroxyvitamin D3 anti-proliferative signaling in lung cancer cells

Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Molecular and Cellular Endocrinology (Impact Factor: 4.41). 02/2012; 355(1):153-61. DOI: 10.1016/j.mce.2012.02.006
Source: PubMed


Human lung tumors aberrantly express the 1α,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))-catabolizing enzyme, CYP24. We hypothesized that CYP24 reduces 1,25(OH)(2)D(3)-mediated transcription and allows lung cancer cells to escape its growth-inhibitory action. To test this, H292 lung cancer cells and the CYP24-selective inhibitor CTA091 were utilized. In H292 cells, CTA091 reduces 1,25(OH)(2)D(3) catabolism, significantly increases 1,25(OH)(2)D(3)-mediated growth inhibition, and increases 1,25(OH)(2)D(3) effects on induced and repressed genes in gene expression profiling studies. Pathway mapping of repressed genes uncovered cell cycle as a predominant 1,25(OH)(2)D(3) target. In H292 cells, 1,25(OH)(2)D(3) significantly decreases cyclin E2 levels and induces G(0)/G(1) arrest. A broader set of cyclins is down-regulated when 1,25(OH)(2)D(3) is combined with CTA091, and cell cycle arrest further increases. Effects of CTA091 on 1,25(OH)(2)D(3) signaling are vitamin D receptor-dependent. These data provide evidence that CYP24 limits 1,25(OH)(2)D(3) anti-proliferative signaling in cancer cells, and suggest that CTA091 may be beneficial in preserving 1,25(OH)(2)D(3) action in lung cancer.

Download full-text


Available from: Pamela A Hershberger, Dec 03, 2014
  • Source
    • "The serum level of 1,25(OH)2D is determined on one hand, from the conversion of the substrate 25(OH)D to the active moiety 1,25(OH)2D by the enzyme 1α-hydroxylase in the kidney, and on the other hand, by its degradation process, the first step of which is the 24-hydroxylation of 1,25(OH)2D. The enzyme 25-hydroxyvitamin D 24-hydroxylase controls degradation of both 25(OH)D into 24,25(OH)2D, and 1,25(OH)2D into 1,24,25(OH)3D [30], [31]. Since currently there is no reliable method to measure 1,24,25(OH)3D, we assessed the 24-hydroxylase activity by measurement of serum 24,25(OH)2D, which was in the normal range and not significantly different in both survivors and non-survivors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In sepsis, the vitamin D active metabolite 1,25-dihydroxyvitamin D (1,25(OH)2D) may play a crucial role by its action to produce cathelicidin and improve endothelial barrier function, such that a deficiency in 1,25(OH)2D is associated with poor outcome. To test our hypothesis, we performed analysis of stored plasma samples from a prospective observational study in 91 patients with sepsis, age of 59.1+/-2.0 years, 52.7% females, and 11.0% deaths at 30 days. Vitamin D status, including 25-hydroxyvitamin D (25(OH)D), 1,25(OH)2D, 24,25-dihydroxyvitamin D (24,25(OH)2D), and parathyroid hormone (PTH), were measured daily over 3 days after hospital admission. At baseline, 1,25(OH)2D was significantly different between survivors vs. non-survivors. But there was no significant difference in 25(OH)D, 24,25(OH)2D, and PTH. In a multivariable binomial logistic regression model, age, total calcium and 1,25(OH)2D were significant predictors of 30-day mortality. Kaplan Meier analysis showed that patients with mean 1,25(OH)2D measured over 3 days of < = 13.6 pg/mL had 57.1% 30-day survival compared to 91.7% in patients with 1,25 (OH)2D level >13.6 pg/mL (p<0.01). From repeated measures regression analysis, there was significant increase in 1,25(OH)2D for increases in 25(OH)D in both survivors and non-survivors. However, compared to survivors, the low 25(OH)D in non-survivors was insufficient to account for the larger decrease in 1,25(OH)2D, indicating a dysfunctional 1α-hydroxylase. Additionally, there was a significant negative correlation between PTH and 1,25(OH)2D in both survivors and non-survivors, suggesting a severe impairment in the effect of PTH to increase renal 1α-hydroxylase activity. In conclusion, low 1,25(OH)2D levels are associated with increased 30-day mortality in sepsis patients, likely due to impaired 25(OH)D hydroxylation and PTH insensitivity. Our data also suggest that the active metabolite 1,25(OH)2D may be an important therapeutic target in the design of sepsis clinical trials.
    PLoS ONE 05/2013; 8(5):e64348. DOI:10.1371/journal.pone.0064348 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We previously demonstrated that non-small cell lung cancer (NSCLC) cells and primary human lung tumors aberrantly express the vitamin D(3)-catabolizing enzyme, CYP24, and that CYP24 restricts transcriptional regulation and growth control by 1α,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) in NSCLC cells. To ascertain the basis for CYP24 dysregulation, we assembled a panel of cell lines that represent distinct molecular classes of lung cancer: cell lines were selected which harbored mutually exclusive mutations in either the K-ras or the Epidermal Growth Factor Receptor (EGFR) genes. We observed that K-ras mutant lines displayed a basal vitamin D receptor (VDR)(low)CYP24(high) phenotype, whereas EGFR mutant lines had a VDR(high)CYP24(low) phenotype. A mutation-associated difference in CYP24 expression was also observed in clinical specimens. Specifically, K-ras mutation was associated with a median 4.2-fold increase in CYP24 mRNA expression (p=4.8×10(-7)) compared to EGFR mutation in a series of 147 primary lung adenocarcinoma cases. Because of their differential basal expression of VDR and CYP24, we hypothesized that NSCLC cells with an EGFR mutation would be more responsive to 1,25(OH)(2)D(3) treatment than those with a K-ras mutation. To test this, we measured the ability of 1,25(OH)(2)D(3) to increase reporter gene activity, induce transcription of endogenous target genes, and suppress colony formation. In each assay, the extent of 1,25(OH)(2)D(3) response was greater in EGFR mutation-positive HCC827 and H1975 cells than in K-ras mutation-positive A549 and 128.88T cells. We subsequently examined the effect of combining 1,25(OH)(2)D(3) with erlotinib, which is used clinically in the treatment of EGFR mutation-positive NSCLC. 1,25(OH)(2)D(3)/erlotinib combination resulted in significantly greater growth inhibition than either single agent in both the erlotinib-sensitive HCC827 cell line and the erlotinib-resistant H1975 cell line. These data are the first to suggest that EGFR mutations may identify a lung cancer subset which remains responsive to and is likely to benefit from 1,25(OH)(2)D(3) administration. This article is part of a Special Issue entitled 'Vitamin D Workshop'.
    The Journal of steroid biochemistry and molecular biology 09/2012; 136(1). DOI:10.1016/j.jsbmb.2012.09.022 · 3.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The active vitamin D hormone 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) plays a major role in regulating calcium homeostasis and bone mineralization. 1,25(OH)(2)D(3) also modulates cellular proliferation and differentiation in a variety of cell types. 24-Hydroxylase, encoded by the CYP24A1 gene, is the key enzyme which converts 1,25(OH)(2)D(3) to less active calcitroic acid. Nearly all cell types express 24-hydroxylase, the highest activity being observed in the kidney. There is increasing evidence linking the incidence and prognosis of certain cancers to low serum 25 (OH)D(3) levels and high expression of vitamin D 24-hydroxylase supporting the idea that elevated CYP24A1 expression may stimulate degradation of vitamin D metabolites including 25-(OH)D(3) and 1,25(OH)(2)D(3). The over expression of CYP24A1 in cancer cells may be a factor affecting 1,25(OH)(2)D(3) bioavailability and anti-proliferative activity pre-clinically and clinically. The combination of 1,25(OH)(2)D(3) with CYP24A1 inhibitors enhances 1,25(OH)(2)D(3) mediated signaling and anti-proliferative effects and may be useful in overcoming effects of aberrant CYP24 expression. This article is part of a Special Issue entitled 'Vitamin D Workshop'.
    The Journal of steroid biochemistry and molecular biology 10/2012; 136(1). DOI:10.1016/j.jsbmb.2012.09.031 · 3.63 Impact Factor
Show more